Very preterm infants who develop bronchopulmonary dysplasia are often treated with dexamethasone (DEXA) to wean them from the ventilator. As DEXA has growth-suppressive and catabolic effects, which might have long-term consequences on growth and organ development, we investigated whether high-dose GH treatment could overcome these effects. In a randomized, double-blind, placebo-controlled trial, 30 ventilated very low birth weight infants were assigned to receive either GH or placebo treatment after start of DEXA. DEXA was given for 24 d (starting dose 0.5 mg · kg
Very preterm infants who develop bronchopulmonary dysplasia are often treated with dexamethasone (DEXA) to wean them from the ventilator. As DEXA has growth-suppressive and catabolic effects, which might have long-term consequences on growth and organ development, we investigated whether high-dose GH treatment could overcome these effects. In a randomized, double-blind, placebo-controlled trial, 30 ventilated very low birth weight infants were assigned to receive either GH or placebo treatment after start of DEXA. DEXA was given for 24 d (starting dose 0.5 mg · kg ), no gain in head circumference, weight, crown-heel length, and knee-heel length occurred in the GH and placebo groups. Growth during the 6-wk study period was not different between the GH and the placebo groups. Two patients in the placebo group died, but the number and the severity of adverse effects was not statistically different between the GH and placebo groups. In conclusion, highdose GH treatment did not improve growth in DEXA-treated very preterm infants and thus cannot be recommended to prevent growth failure in these infants. During high-dose DEXA, a complete growth arrest occurred, including stunting of head growth. Growth in head circumference and weight with lower dose DEXA was comparable to growth after discontinuation of DEXA. In very preterm infants, the development of bronchopulmonary dysplasia (BPD) is a major problem. According to the latest classification, BPD is evaluated at 36 wk postmenstrual age or at discharge from the neonatal intensive care unit (NICU), whichever comes first, and is defined as a persistent need for supplemental oxygen for at least 28 d with a persistence of respiratory features, such as retractions, tachypnea, and rales as a result of respiratory disease (1) . The incidence of BPD increases from 12% in infants with a gestational age of 30 wk to 30 -40% in those who are born after a gestational age of 25-26 wk (2,3).
In NICUs, systemic corticosteroids are often given to wean very preterm infants with severe and prolonged respiratory problems from the ventilator (4 -6). Many infants who are at risk for development of BPD are treated with dexamethasone (DEXA). DEXA treatment in preterm infants is known to have an inhibiting effect on weight gain as well as linear growth and head circumference (7) (8) (9) (10) (11) . Follow-up studies suggest impairment in brain growth and persisting growth retardation into childhood (12-16).
Corticosteroids have a suppressive effect on pituitary GH secretion in children (17) . In a previous study, we demonstrated a significant DEXA-induced decline in serum GH levels in ventilated very preterm infants (18) . Several studies suggested that the growth-inhibiting effect of DEXA might be overcome by high-dose GH treatment and demonstrated a beneficial effect of GH treatment on linear growth and on neurodevelopment in steroid-treated older children (19, 20) . As the effects of DEXA in preterm infants might have short-term as well as long-term consequences on longitudinal growth and organ development, we performed a randomized, double-blind, placebo-controlled GH trial in ventilated very preterm infants who were treated with DEXA to evaluate whether recombinant GH overcomes the growth-inhibiting effects of DEXA treatment.
METHODS
Patients. Between July 1997 and July 2000, 30 ventilated very preterm infants who were born at a gestational age Յ32 wk and were at risk for developing BPD were included at the moment DEXA treatment was initiated to wean them from the ventilator. The indication to start DEXA treatment was made by the attending neonatologist and based on a persistent need for artificial ventilation and oxygen dependence accompanied by an abnormal chest x-ray. Patients were excluded when they had a persistent ductus arteriosus, pulmonary infection, or sepsis at randomization or when they had a grade 3 or 4 intraventricular hemorrhage, chromosomal defect, or major congenital anomalies. Patients were also excluded when the mother was treated for an endocrine disorder with GH, thyroxin, or thyreostatic drugs. All patients were admitted to the NICU of the Sophia Children's Hospital in Rotterdam, The Netherlands. The Medical Ethics Committee of the Erasmus University Medical Center approved the study protocol, and written informed consent was obtained from the parents of each child.
Study design and randomization. A randomized, double-blind, placebocontrolled GH trial in ventilated very preterm infants who were treated with DEXA was performed. The primary outcome was growth of head circumference and linear length and gain in weight 6 wk after start of treatment.
Directly after inclusion, all patients started with DEXA treatment and were randomly and blindly assigned to receive recombinant human GH 0.3 mg · kg Ϫ1 · d Ϫ1 (Norditropin R; Novo Nordisk A/S Netherlands Alphen)) or placebo treatment (Novo Nordisk A/S) administered once daily by s.c. injection for a period of 6 wk. As there is hardly any information about neonatal GH treatment, we used a similar dosage as described in a study that was performed during the neonatal period in term infants who were small for gestational age (SGA) to obtain supraphysiologic serum GH levels (21) . GH or placebo treatment was started within 4 -6 h after start of DEXA. DEXA treatment was started with a dosage of 0.5 mg · kg Study procedures. All patients underwent a physical examination before start of DEXA. Attending neonatologists, investigators, and parents were unaware of the treatment allocation because of the double-blind design.
The attending neonatologist provided routine care and feeding decisions. According to the policy of the NICU, infants were started on parenteral nutrition on the second day of life, and enteral feedings were initiated on day 7.
Serum GH levels were measured, and in infants with an arterial line, a 6-h GH profile was performed. Because it was considered unethical to withdraw Ͼ5% of the total blood volume for study purposes, a longer sampling period and more frequent blood sampling was considered unacceptable. Serum IGF-I and IGF-binding protein-3 (IGFBP-3) levels were measured before as well as 3 and 6 wk after start of DEXA.
Severity of respiratory failure at start of DEXA was assessed by calculating the ventilation score (mean airway pressure ϫ inspired fraction of oxygen). Possible adverse effects of DEXA and of GH treatment, such as need for antihypertensive or insulin treatment, cardiac hypertrophy, and incidence and severity of retinopathy of prematurity (ROP), were recorded. Nutritional intake was calculated from the daily nutritional intake.
Cardiologic evaluation. Cardiologic evaluation was performed before, during, and after stopping DEXA treatment. M-mode echocardiography was used according to the recommendations of the American Society of Echocardiography (22) . The occurrence of left ventricular hypertrophy was assessed and defined as a relative wall thickness (RWTh) of the left ventricle Ͼ0.2. RWTh was calculated by dividing the posterior wall thickness of the left ventricle by the left ventricle internal dimension measured at end diastole.
Anthropometric measurements. Weight, recumbent crown-heel length, knee-heel length, and head circumference were measured. All anthropometric measurements were done by two experienced people. Baseline measurements were performed before DEXA was started. Weight was measured daily; head circumference and crown-heel length were measured weekly. Knee-heel length was measured twice a week. The time of measurements was recorded and calculated as hours from the start of DEXA administration.
Crown-heel length was measured using a neonatometer in the incubator, with full extension of the hips and knees and with both heels pressing the end of the neonatometer. The mean of three readings was used for analysis. Weight was measured on an electronic baby scale (TEC, Tokyo Electronic Co., Tokyo, Japan), every day at the same time. Head circumference was measured three times using a standard plastic measuring tape. The mean of three readings was used for analysis. Knee-heel length was measured according to Gibson with a hand-held knemometer (7) . The mean of eight readings was used for analysis. The investigator performed the measurements but remained blind for the readings, which were performed and recorded by an observer.
The coefficients of variation for both observers for crown-heel length were 0.3 and 0.4%, for weight were 0.4 and 0.4%, for knee-heel length were 0.6 and 0.7%, and for occipito-frontal head circumference were 0.1 and 0.2%, respectively. Birth weight was expressed as SD scores for gestational age according to the standards of Usher and McLean (23) . Small for gestational age was defined as a birth weight SD score ϽϪ2.
Hormone assays. All hormone determinations were performed in the Endocrine Laboratory of the Erasmus University Hospital Rotterdam, the Netherlands. Serum GH levels were measured using a two-site immunoradiometric assay (ELSA-HGH; CIS bio international, ORIS Group, France). The World Health Organization First International Reference Preparation WHO 80/505 was used as a standard. The intra-and interassay coefficients of variation were Ͻ2.8 and Ͻ4.4%, respectively.
Serum IGF-I levels were determined by RIA (SM-C-RIA-CT; Biosource Europe SA). Intra-and interassay coefficients of variation were Ͻ6.1 and 9.9%, respectively. Cross-reactivity with IGF-II, insulin, and GH was 0.2, Ͻ0.001, and Ͻ0.01%, respectively. Serum IGFBP-3 levels were determined using a two-site immunoradiomet--ric assay (IGF-BP3 IRMA, DSL-6600; Diagnostic Systems Laboratories, Webster, TX). Intra-and interassay coefficients of variation were Ͻ3.9 and 1.9%, respectively.
Statistical analysis. Statistical analyses were performed using SPSS 9.0 for Windows 95 (SPSS software, Chicago, IL) or SAS version 6.12 for Windows (SAS Institute Inc., Cary, NC). Visual inspection of scatter plots of anthropometric data showed stable values during the first week for all parameters but an increase thereafter. Therefore, these data were analyzed using piecewise linear regression ("broken-stick" method), with a breakpoint at day 7 (24) . In a secondary analysis, the effect of discontinuation of DEXA was investigated using the same method. This was done by allowing for a second breakpoint for each patient individually at the day of discontinuation of DEXA. These analyses were done using repeated measurements ANOVA, and calculations for this particular analysis were done with SAS software (random coefficients model from SAS PROC MIXED). Weight and hormone values were logarithmically transformed before analysis to obtain approximate normal distributions. Percentages were compared using Fisher's exact test. Two-sided p Յ 0.05 were considered significant.
RESULTS

Clinical characteristics.
Thirty patients were included in the study. Fifteen patients were treated with GH, and 15 patients received placebo, in addition to DEXA. The clinical data of the patients before start and during the study are shown in Tables 1  and 2 . Three infants in the GH and five infants in the placebo group were born SGA. Most infants received 24 d of DEXA, but one infant in the GH group and one infant in the placebo group received a second course DEXA. In the placebo group, one patient died at day 3 as a result of progressive respiratory insufficiency.
Anthropometry. We first analyzed the anthropometric data for differences between treatment and placebo groups. No significant differences were found for any of the measures (Table 3) . We then pooled the data from both groups to evaluate the effect of dexamethasone treatment. We found that 
, there was no increase in any measurement, showing a complete growth arrest including head growth. During the remainder of the study period, increases in weight, head circumference, crown-heel length, and knee-heel length were significantly different from week 1 (all p Ͻ 0.001; Fig. 1 ).
Comparing growth after cessation of DEXA with growth while on lower doses of DEXA (weeks 2 and 3) showed no significant increase in head circumference and weight in both treatment groups and no increase in crown-heel length and knee-heel length in the placebo group (Table 3 ). In the GH group, the increase in crown-heel length and knee-heel length after discontinuation of DEXA was significantly higher than during weeks 2 and 3 on DEXA (p ϭ 0.028 and p ϭ 0.022, respectively).
Serum hormone levels. In six infants who were treated with GH, serum GH profiles were performed (Fig. 2) . Serum GH levels in the GH group varied between 1.4 and 518 g/L. High GH levels after administration of GH were followed by a rapid decline to Ͻ5 g/L, just before administration of the next dose. In three patients serum GH half-life was 1.9, 5.2, and 5.5 h, respectively.
In both the GH and placebo groups, neither start nor discontinuation of DEXA resulted in a change in serum IGF-I levels from baseline. At day 21, serum IGF-I levels were not significantly different between the groups (Table 4) . Serum IGFBP-3 levels during DEXA were higher compared with baseline levels in both groups (p Ͻ 0.02) but not different between the groups (p ϭ 0.15). Serum IGFBP-3 levels did not change after discontinuation of DEXA in both groups (p ϭ 0.46).
Adverse effects. The number of infants who received antihypertensive or insulin treatment was similar in the placeboand GH-treated groups. Two patients in the placebo group and none in the GH group died. The number of infants who developed BPD or severe ROP on follow-up until 36 wk postconceptional age was not different between the groups. Left ventricular hypertrophy measured by RWTh of the left ventricle occurred in the majority of infants in both groups during DEXA treatment and was not significantly different between the groups.
DISCUSSION
This is the first placebo-controlled GH study to measure the effect of GH versus placebo in combination with DEXA treat- 708 ment on growth in very preterm infants. There were four major findings in this study. First, GH treatment had no effect in preventing impairment of growth in DEXA-treated preterm infants when a GH dose of 0.3 mg · kg Ϫ1 · d Ϫ1 was given for a 6-wk period. Second, a complete growth arrest as a result of DEXA treatment was associated with high-dose DEXA treatment. Third, growth in head circumference and weight during lower dose of DEXA was comparable to growth after cessation of DEXA. Fourth, after discontinuation of DEXA, an increase in linear growth (crown-heel length and knee-heel length) was observed.
Nowadays, the use of DEXA in very preterm infants to wean them from the ventilator is an area of great concern, especially when high doses of glucocorticoids are given. DEXA treatment in very preterm infants has been associated with reduced cerebral cortical gray matter, an arrest of alveolarization of the lungs, catabolic effects, alteration of skeletal metabolism, and cessation of growth (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (25) (26) (27) . Despite these substantial concerns, DEXA is still administered to very preterm infants to wean them from the ventilator when clinical and radiologic signs of BPD develop and conservative treatment such as increased ventilation settings, fluid restriction, diuretics, antibiotics, and inhalation therapy has failed (28) . The starting dose of DEXA that is usually given to very preterm infants is 0.5 mg · kg Ϫ1 · d Ϫ1 for 3 d, which might be equivalent to as much as 20 mg/kg or more of hydrocortisone in biologic effect.
In the present study, weight, crown-heel length, knee-heel length, and head circumference were measured accurately with minimal intra-and interobserver variations, which allowed evaluation of growth on a weekly basis. During the first week, a high dose of DEXA (0.5 mg/kg) for 3 d was given, followed by a dose of 0.3 mg/kg for 3 d and 0.25 mg/kg for 3 d. When the daily DEXA dose was decreased to Ͻ0.25 or 0.20 mg · kg Ϫ1 · d Ϫ1 , the growth of head circumference and weight was similar to the growth rate after discontinuation of DEXA. Apparently, there was a dose-effect relationship of DEXA as described in older children (29) . Because the present studies show an association between DEXA treatment in the neonatal period and a decrease in cortical gray matter and neurologic impairment, the fact that we did find stunted growth of head circumference with the use of high-dose DEXA (0.5 to 0.25 mg · kg Ϫ1 · d Ϫ1 ) might have major implications for future use of DEXA in very preterm infants. 
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Several studies reported reduced growth during DEXA treatment in preterm infants (7, 9, 11, 30, 31) . Although the duration of DEXA treatment varied in these studies, the initial dose of DEXA used in most studies was 0.5 to 0.6 mg · kg Ϫ1 · d Ϫ1 and gradually tapered off as in our study. In one study in 10 preterm infants, reduced growth of weight, head circumference, and crown-heel length was observed during the first 2 wk on DEXA compared with weeks 3 and 4. Although there was a great variation in duration of DEXA treatment (10 -70 d), these data suggest that the dose of DEXA was negatively correlated with growth (31) . In another study, comparing the effect of a 6-wk course of DEXA with a 3-d pulse of DEXA every 10 d, the higher cumulative dose in the 6-wk DEXA group resulted in a lower increase in knee-heel length during the first 2 wk of DEXA (9) . In addition to these studies, the study by Stark et al. (11) starting with a lower DEXA dose of 0.15 mg · kg Ϫ1 · d
Ϫ1
within 24 h after birth showed a decrease in weight and head circumference at 36 wk postmenstrual age. Although which dose of DEXA induces a reduction of growth was not described precisely, all studies point to a possible dose-related and maybe an age-related effect of DEXA. Very limited data are available on GH treatment in the neonatal period in either term or preterm infants. In one study, treatment with recombinant GH (0.3 mg · kg Ϫ1 · d Ϫ1 ) in preterm infants who were born SGA did not have any effect on growth and body composition during the neonatal period (21) . It is known that the GH/IGF-I ratio in infants who are born SGA is higher than in infants who are born appropriate for gestational age during the neonatal period, suggesting a higher GH insensitivity in infants who are SGA compared with appropriate for gestational age, at least directly after birth. Therefore, the results of the GH study in infants who were SGA cannot be applied directly to other preterm infants. Although three infants in the GH group were born SGA, we believe that this cannot explain our results.
On the basis of our results, it can be concluded that GH treatment, even in a high dose, is not effective to improve growth in very preterm infants during DEXA treatment in the neonatal period. For comparison, the administered GH dose was 10 times the dose prescribed to GH-deficient children. Possible explanations for this result might be the high dose of glucocorticoids and/or GH insensitivity in very preterm infants.
The DEXA dose used in preterm infants is much higher than the dosages used in older, prednisone-treated children in which GH treatment was shown to be effective. Improvements of weight and height velocity with GH treatment are reported in children who receive glucocorticoids dosages equivalent to 0.1-0.5 mg · kg Ϫ1 · d Ϫ1 prednisone in chronic diseases such as asthma, lupus, and autoimmune colitis and after renal transplantation (20, 32, 33) . Also in these older children, the effect of GH treatment is dependent on the dose of glucocorticoids used (34) .
Serum GH levels that were measured in our infants who received GH treatment were very high but did not result in higher IGF-I levels, indicating GH insensitivity in these preterm infants, which might explain the lack of effect of GH treatment. The mechanisms by which DEXA induces growth retardation are still poorly understood. In an earlier study in very preterm infants, we did not find a decline in serum IGF-I levels 2 d after starting DEXA, and also in the present study, no change in serum IGF-I during DEXA treatment was observed (18) . It might well be that serum IGF-I levels do not decline during DEXA treatment and that the observed growth inhibition by DEXA in earlier studies (35) is due to a direct effect of DEXA on the epiphyseal cartilage by inhibition of the local secretion and paracrine action of IGF-I (36). Prednisone causes in vitro a 46% fall in IGF-I bioactivity and has a suppressive effect on IGF mRNA in the tibia, liver, lung, and kidney in the rat, without causing significant changes in serum immunoreactive IGF-I levels (37, 38) . Thus, DEXA-induced No difference in the occurrence of adverse effects such as cardiac hypertrophy, hyperglycemia, hypertension, and retinopathy and mortality was found between the GH and the placebo groups. Two patients in the placebo group died. Insulin requirement because of hyperglycemia occurred in both groups and was most likely caused by insulin resistance as a result of DEXA. GH treatment did not increase the need for insulin and did not result in an increase in cardiac hypertrophy compared with the placebo group. This in contrast to adults, in whom a low dose of GH increases left ventricular mass and an excess of GH is associated with cardiac hypertrophy (39, 40) . In our GH-treated patients, we did not find an increase in severe ROP, although recent studies suggest an association between the persistence of high GH levels in preterm infants and the development of severe retinopathy (41) . Although treatment with GH did not result in a positive effect on growth in the short term, we are planning a long-term follow-up to investigate whether there is any effect on growth, neurodevelopment, and lung function.
In conclusion, GH treatment had no effect in preventing impairment of growth in DEXA-treated preterm infants when a GH-dose of 0.3 mg · kg Ϫ1 · d Ϫ1 was given for a 6-wk period. Despite GH treatment, no growth in head circumference, weight, crown-heel length, and knee-heel length occurred during high-dose DEXA treatment. Therefore, the use of GH in the neonatal period cannot be recommended to prevent growth failure in DEXA-treated preterm infants. Second, a complete growth arrest, including stunting of head growth, occurred during high-dose DEXA treatment (0.5-0.25 mg · kg Ϫ1 · d Ϫ1 ). Growth in head circumference and weight with lower doses of DEXA was comparable to growth after discontinuation of DEXA, indicating a dose-related growth-limiting effect of DEXA.
